

2 March 2011

PRESS RELEASE:

European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan
Chairman Masuhiro Kato

About Enactment of “JPMA Transparency Guideline” - EFPIA Japan Chairman Statement -

Today, at the plenary meeting of the Japan Pharmaceutical Manufacturers Association (hereinafter referred to as “JPMA”), the “Guideline for Transparent Relation between Corporate Activities and Medical Institutions / Healthcare Professionals” (hereinafter referred to as “Transparency Guideline”) was enacted. In this respect, Masuhiro Kato, Chairman, European Federation of Pharmaceutical Industries and Associations (hereinafter referred to as “EFPIA”) Japan announced the following comment.

EFPIA Japan has considered since before that it is a social demand to make transparent the activities of pharmaceutical companies and resolve the issue of benefit conflict and has deliberated disclosure of information on payments to healthcare professionals.

For new drug development, the basic researches and the various processes based on the Pharmaceutical Affairs Law including clinical studies are necessary, and it is said that a long term exceeding 10 years and enormous money reaching 50-100 billion yen are necessary to develop one new drug. Also after marketing a new drug, it is obligated to investigate the use status and report the relevant adverse events as information collection for promotion of proper use.

As for the expenses necessary for drug creation and promotion of proper use, the pharmaceutical companies are paying adequate considerations to medical institutions and

healthcare professionals in compliance with the Pharmaceutical Affairs Law, “Promotion Code”, “Fair Competition Code”, etc. after finalizing contracts.

We recognize that it is important to disclose the information on the relation between pharmaceutical companies and medical institutions or healthcare professionals and increase the transparency for requesting general citizens to understand that the activities are conducted under the high ethical standards

Based also on the trend in the Western countries, EFPIA Japan has been engaged in this issue in collaboration with JPMA. EFPIA Japan welcomes that JPMA enacted this Transparency Guideline today and would like to promote highly transparent corporate activities by the member companies according to this Transparency Guideline with the understanding of the stakeholders (interested individuals).

In addition, recently, laws to prevent corporate foul actions including Foreign Corrupt Practices Act in the United States and Bribery Act 2010 in the United Kingdom are newly enacted. EFPIA Japan would like to make proposals for environmental arrangements so that corporate activities contributing to the benefit of patients according to the global standards, i.e., with ethics of the highest level, will be conducted also in Japan.

The end

◇ Contact information:

Hideto Kita, Chairman, Public Relations Committee, EFPIA Japan (Public Relations Department, Novartis Pharma)

Phone: 03-3797-8009